SNX21

Across TCGA pan-cancer cohorts, SNX21 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SNX21 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SNX21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNX21 expression acts as an unfavorable survival marker.

STAD, COAD, and SARC are the cancer types where SNX21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	24	view →
COAD	OS	Median	All	0.001	0.871	<.001	18	view →
SARC	DFS	Median	All	0.086	0.611	<.001	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SKCM	DFS	Median	All	0.192	0.757	.022	9	view →
CESC	OS	Median	All	0.277	0.798	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SNX21–STAD (OS)

Open the STAD breakdown →